- Home
- GIGM vs CARM Comparison
GIGM vs CARM Comparison
Compare GIGM & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- CARM
- Stock Information
- Founded
- GIGM 1998
- CARM 2016
- Country
- GIGM Taiwan
- CARM United States
- Employees
- GIGM N/A
- CARM N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- CARM Health Care
- Exchange
- GIGM Nasdaq
- CARM Nasdaq
- Market Cap
- GIGM 16.1M
- CARM 16.4M
- IPO Year
- GIGM 2000
- CARM N/A
- Fundamental
- Price
- GIGM $1.43
- CARM $0.39
- Analyst Decision
- GIGM
- CARM Hold
- Analyst Count
- GIGM 0
- CARM 5
- Target Price
- GIGM N/A
- CARM $0.90
- AVG Volume (30 Days)
- GIGM 5.7K
- CARM 1.7M
- Earning Date
- GIGM 07-30-2025
- CARM 08-07-2025
- Dividend Yield
- GIGM N/A
- CARM N/A
- EPS Growth
- GIGM N/A
- CARM N/A
- EPS
- GIGM N/A
- CARM N/A
- Revenue
- GIGM $3,103,000.00
- CARM $19,964,000.00
- Revenue This Year
- GIGM N/A
- CARM N/A
- Revenue Next Year
- GIGM N/A
- CARM N/A
- P/E Ratio
- GIGM N/A
- CARM N/A
- Revenue Growth
- GIGM N/A
- CARM 32.45
- 52 Week Low
- GIGM $1.27
- CARM $0.14
- 52 Week High
- GIGM $1.80
- CARM $1.31
- Technical
- Relative Strength Index (RSI)
- GIGM 48.05
- CARM 50.72
- Support Level
- GIGM $1.40
- CARM $0.38
- Resistance Level
- GIGM $1.49
- CARM $0.44
- Average True Range (ATR)
- GIGM 0.06
- CARM 0.04
- MACD
- GIGM -0.00
- CARM -0.01
- Stochastic Oscillator
- GIGM 28.12
- CARM 32.53
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.